We are live on ! Find out more
ARDS

Aridis Pharmaceuticals Inc. Common Stock
ARDS

Delisted

ARDS was delisted on the 18th of July, 2023.

Back to rankings

4 hedge funds and large institutions have $161K invested in Aridis Pharmaceuticals Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.51% less ownership

Funds ownership: 0.69% → 0.18% (-0.51%)

33% less funds holding

Funds holding: 6 → 4 (-2)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

78% less capital invested

Capital invested by funds: $725K → $161K (-$564K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$2.48K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$370K
2
Millennium Management
Millennium Management
New York
-$131K
3
SPIA
Steward Partners Investment Advisory
New York
-$13K
4
TRCT
Tower Research Capital (TRC)
New York
-$5.33K

ARDS Hedge Fund Activity: Q4 2018 in Review

4 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q4 2018, worth a combined $161K — down 78% from $725K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ARDS and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $2.48K. The largest seller was Goldman Sachs, exiting entirely with an estimated $370K sold.

  • 4 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q4 2018, down from 6 in Q3 2018.
  • Funds reported $161K of Aridis Pharmaceuticals Inc. Common Stock stock for Q4 2018, down 78% quarter-over-quarter.
  • 0 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q4 2018 and 2 closed out, a net change of -2 holders.
  • The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q4 2018 was UBS Group, an estimated $2.48K added.
  • The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q4 2018 was Goldman Sachs, an estimated $370K sold.

Based on aggregated 13F filings for Q4 2018.